Artificial Intelligence Approach in Prostate Cancer Diagnosis: Bibliometric Analysis
Chronological Development of Artificial Intelligence Approach in Prostate Cancer Diagnosis
Full Text


Artificial Intelligence
Prostate Cancer
Gleason Score
Bibliometric Analysis

How to Cite

Denysenko, A., Savchenko, T., Dovbysh, A., Romaniuk, A., & Moskalenko, R. (2022). Artificial Intelligence Approach in Prostate Cancer Diagnosis: Bibliometric Analysis. Galician Medical Journal, 29(2), E202225.


Background. Prostate cancer is one of the most common male malignancies worldwide that ranks second in cancer-related mortality. Artificial intelligence can reduce subjectivity and improve the efficiency of prostate cancer diagnosis using fewer resources as compared to standard diagnostic scheme.

This review aims to highlight the main concepts of prostate cancer diagnosis and artificial intelligence application and to determine achievements, current trends, and potential research directions in this field, using bibliometric analysis.

Materials and Methods.The studies on the application of artificial intelligence in the morphological diagnosis of prostate cancer for the past 35 years were searched for in the Scopus database using “artificial intelligence” and “prostate cancer” keywords. The selected studies were systematized using Scopus bibliometric tools and the VOSviewer software.

Results. The number of publications in this research field has drastically increased since 2016, with most research carried out in the United States, Canada, and the United Kingdom. They can be divided into three thematic clusters and three qualitative stages in the development of this research field in timeline aspect.

Conclusions. Artificial intelligence algorithms are now being actively developed, playing a huge role in the diagnosis of prostate cancer. Further development and improvement of artificial intelligence algorithms have the potential to automate and standardize the diagnosis of prostate cancer.
Full Text


Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, et al. Epidemiology and prevention of prostate cancer. European Urology Oncology. 2021;4(6):877–892. Available from:

Mamidi TKK, Wu J, Hicks C. Mapping the germline and somatic mutation interaction landscape in indolent and aggressive prostate cancers. Journal of Oncology. 2019;2019:1–15. Available from:

Knudsen BS, Vasioukhin V. Mechanisms of prostate cancer initiation and progression. Advances in Cancer Research. 2010;109:1–50. Available from:

Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, et al. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiology Biomarkers & Prevention. 2010;19(10):2611–2622. Available from:

Deng T, Xiao Y, Dai Y, Xie L, Li X. Roles of key epigenetic regulators in the gene transcription and progression of prostate cancer. Frontiers in Molecular Biosciences. 2021;8:743376. Available from:

Kumaraswamy A, Welker Leng KR, Westbrook TC, Yates JA, Zhao SG, Evans CP, et al. Recent advances in epigenetic biomarkers and epigenetic targeting in prostate cancer. European Urology. 2021;80(1):71–81. Available from:

Veltri RW, Christudass CS. Nuclear morphometry, epigenetic changes, and clinical relevance in prostate cancer. In: Schirmer E, de las Heras J, editors. Cancer Biology and the Nuclear Envelope. Advances in Experimental Medicine and Biology. New York, NY: Springer; 2014. 77–99. Available from:

Carleton NM, Lee G, Madabhushi A, Veltri RW. Advances in the computational and molecular understanding of the prostate cancer cell nucleus. Journal of Cellular Biochemistry. 2018;119(9):7127–7142. Available from:

Van Booven DJ, Kuchakulla M, Pai R, Frech FS, Ramasahayam R, Reddy P, et al. A systematic review of artificial intelligence in prostate cancer. Research and Reports in Urology. 2021;13:31–39. Available from:

Costa DN, Pedrosa I, Donato F, Roehrborn CG, Rofsky NM. MR imaging–transrectal US fusion for targeted prostate biopsies: implications for diagnosis and clinical management. RadioGraphics. 2015;35(3):696–708. Available from:

Samtani S, Burotto M, Roman JC, Cortes-Herrera D, Walton-Diaz A. MRI and targeted biopsy essential tools for an accurate diagnosis and treatment decision making in prostate cancer. Diagnostics. 2021;11(9):1551. Available from:

Greer MD, Lay N, Shih JH, Barrett T, Bittencourt LK, Borofsky S, et al. Computer-aided diagnosis prior to conventional interpretation of prostate mpMRI: an international multi-reader study. European Radiology. 2018;28(10):4407–4417. Available from:

Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. Journal of Urology. 1974;111(1):58–64. Available from:

Egevad L, Cheville J, Evans AJ, Hörnblad J, Kench JG, Kristiansen G, et al. Pathology Imagebase - a reference image database for standardization of pathology. Histopathology. 2017;71(5):677–685. Available from:

Epstein JI, Amin MB, Fine SW, Algaba F, Aron M, Baydar DE, et al. The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer. Archives of Pathology & Laboratory Medicine. 2020;145(4):461–493. Available from:

Epstein JI. Prostate cancer grading: a decade after the 2005 modified system. Modern Pathology. 2018;31(S1):47–63. Available from:

Kwak JT, Hewitt SM. Multiview boosting digital pathology analysis of prostate cancer. Computer Methods and Programs in Biomedicine. 2017;142:91–99. Available from:

Harmon SA, Tuncer S, Sanford T, Choyke PL, Turkbey B, et al. Artificial intelligence at the intersection of pathology and radiology in prostate cancer. Diagnostic and Interventional Radiology. 2019;25(3):183–188. Available from:

Kallen H, Molin J, Heyden A, Lundstrom C, Astrom K. Towards grading gleason score using generically trained deep convolutional neural networks. 2016 IEEE 13th International Symposium on Biomedical Imaging (ISBI). 2016. Available from:

Zhou N, Fedorov A, Fennessy F, Kikinis R, Gao Y. Large scale digital prostate pathology image analysis combining feature extraction and deep neural network. 2017. Available from:

del Toro JO, Atzori M, Otálora S, Andersson M, Eurén K, Hedlund M, et al. Convolutional neural networks for an automatic classification of prostate tissue slides with high-grade Gleason score. In: Gurcan MN, Tomaszewski JE, editors. Medical Imaging 2017: Digital Pathology. SPIE Proceedings. Orlando, Florida, United States. 2017. Available from:

Doyle S, Feldman MD, Shih N, Tomaszewski J, Madabhushi A. Cascaded discrimination of normal, abnormal, and confounder classes in histopathology: Gleason grading of prostate cancer. BMC Bioinformatics. 2012;13(1):282. Available from:

Doyle S, Feldman M, Tomaszewski J, Madabhushi A. A boosted bayesian multiresolution classifier for prostate cancer detection from digitized needle biopsies. IEEE Transactions on Biomedical Engineering. 2012;59(5):1205–1218. Available from:

Xu J, Luo X, Wang G, Gilmore H, Madabhushi A. A deep convolutional neural network for segmenting and classifying epithelial and stromal regions in histopathological images. Neurocomputing. 2016;191:214–223. Available from:

Litjens G, Sánchez CI, Timofeeva N, Hermsen M, Nagtegaal I, Kovacs I, et al. Deep learning as a tool for increased accuracy and efficiency of histopathological diagnosis. Scientific Reports. 2016;6(1):26286. Available from:

Nir G, Hor S, Karimi D, Fazli L, Skinnider BF, Tavassoli P, et al. Automatic grading of prostate cancer in digitized histopathology images: learning from multiple experts. Medical Image Analysis. 2018;50:167–180. Available from:

Nagpal K, Foote D, Tan F, Liu Y, Chen P-HC, Steiner DF, et al. Development and validation of a deep learning algorithm for Gleason grading of prostate cancer from biopsy specimens. JAMA Oncology. 2020;6(9):1372-1380. Available from:

Campanella G, Hanna MG, Geneslaw L, Miraflor A, Werneck Krauss Silva V, Busam KJ, et al. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nature Medicine. 2019;25(8):1301–1309. Available from:

Bulten W, Balkenhol M, Belinga J-JA, Brilhante A, Çakır A, Egevad L, et al. Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. Modern Pathology. 2020;34(3):660–671. Available from:

Ström P, Kartasalo K, Olsson H, Solorzano L, Delahunt B, Berney DM, et al. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. The Lancet Oncology. 2020;21(2):222–232. Available from:

Pantanowitz L, Quiroga-Garza GM, Bien L, Heled R, Laifenfeld D, Linhart C, et al. An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study. The Lancet Digital Health. 2020;2(8):e407–e416. Available from:

Rashid S, Fazli L, Boag A, Siemens R, Abolmaesumi P, Salcudean SE. Separation of benign and malignant glands in prostatic adenocarcinoma. In: Mori K, Sakuma I, Sato Y, Barillot C, Navab N, editors. Medical Image Computing and Computer-Assisted Intervention – MICCAI 2013. MICCAI 2013. Lecture Notes in Computer Science, vol 8151. Berlin, Heidelberg: Springer; 2013. pp.461–468. Available from:

Gertych A, Ing N, Ma Z, Fuchs TJ, Salman S, Mohanty S, et al. Machine learning approaches to analyze histological images of tissues from radical prostatectomies. Computerized Medical Imaging and Graphics. 2015;46:197–208. Available from:

Singh M, Kalaw EM, Giron DM, Chong K-T, Tan CL, Lee HK. Gland segmentation in prostate histopathological images. Journal of Medical Imaging. 2017;4(2):027501. Available from:

Lu C, Romo-Bucheli D, Wang X, Janowczyk A, Ganesan S, Gilmore H, et al. Nuclear shape and orientation features from H&E images predict survival in early-stage estrogen receptor-positive breast cancers. Laboratory Investigation. 2018;98(11):1438–1448. Available from:

Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, et al. Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images. Cell Reports. 2018;23(1):181-193.e7. Available from:

Rezaeilouyeh H, Mollahosseini A, Mahoor MH. Microscopic medical image classification framework via deep learning and shearlet transform. Journal of Medical Imaging. 2016;3(4):044501. Available from:

Ayyad SM, Shehata M, Shalaby A, Abou El-Ghar M, Ghazal M, El-Melegy M, et al. Role of AI and histopathological images in detecting prostate cancer: a survey. Sensors. 2021;21(8):2586. Available from:

Hameed BMZ, S. Dhavileswarapu AVL, Raza SZ, Karimi H, Khanuja HS, Shetty DK, et al. Artificial intelligence and its impact on urological diseases and management: a comprehensive review of the literature. Journal of Clinical Medicine. 2021;10(9):1864. Available from:

Kartasalo K, Bulten W, Delahunt B, Chen P-HC, Pinckaers H, Olsson H, et al. Artificial intelligence for diagnosis and Gleason grading of prostate cancer in biopsies—current status and next steps. European Urology Focus. 2021;7(4):687–91. Available from:

Mobadersany P, Yousefi S, Amgad M, Gutman DA, Barnholtz-Sloan JS, Velázquez Vega JE, et al. Predicting cancer outcomes from histology and genomics using convolutional networks. Proceedings of the National Academy of Sciences. 2018;115(13):E2970-E2979. Available from:

Pai RK, Van Booven DJ, Parmar M, Lokeshwar SD, Shah K, Ramasamy R, et al. A review of current advancements and limitations of artificial intelligence in genitourinary cancers. American Journal of Clinical and Experimental Urology. 2020;8(5):152-162. Available from:

Tran KA, Kondrashova O, Bradley A, Williams ED, Pearson JV, Waddell N. Deep learning in cancer diagnosis, prognosis and treatment selection. Genome Medicine. 2021;13(1):152. Available from:

Nagpal K, Foote D, Liu Y, Chen P-HC, Wulczyn E, Tan F, et al. Development and validation of a deep learning algorithm for improving Gleason scoring of prostate cancer. npj Digital Medicine. 2019;2(1):48. Available from:

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.